SCHEMBL23980832

SCHEMBL23980832

OCC(O)c1ccc(Cl)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.51
PYGL P06737 5/20 0.51
PDE2A O00408 1/20 0.41
MDM2 Q00987 1/20 0.39
SCN9A Q15858 4/20 0.37
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
ADRA2C P18825 2/20 0.36
ADRB2 P07550 1/20 0.36
CYP3A4 P08684 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA1A P35348 1/20 0.36
GRIN2B Q13224 1/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217483 1.00 KCNH2 (0.51) KCNH2PYGLPDE2AMDM2SCN9A
SCHEMBL30446626 0.87 KCNH2 (0.50) KCNH2PYGLPDE2AMDM2PSEN1
SCHEMBL22206866 0.87 KCNH2 (0.50) KCNH2PYGLPDE2AMDM2PSEN1
SCHEMBL22206894 0.87 KCNH2 (0.50) KCNH2PYGLPDE2AMDM2PSEN1
SCHEMBL30446289 0.87 KCNH2 (0.50) KCNH2PYGLPDE2AMDM2PSEN1
SCHEMBL30445833 0.87 KCNH2 (0.50) KCNH2PYGLPDE2AMDM2PSEN1
SCHEMBL3195180 0.87 KCNH2 (0.50) KCNH2PYGLPDE2AMDM2PSEN1
SCHEMBL18482272 0.85 KCNH2 (0.51) KCNH2PYGLPDE2AMDM2ADRA2C
SCHEMBL20235913 0.85 KCNH2 (0.51) KCNH2PYGLPDE2AMDM2ADRA2C
SCHEMBL14920728 0.83 PDE2A (0.60) KCNH2PYGLPDE2AMDM2ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552791-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-02-17 US disclosed
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2025-07-03 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
CN-115667250-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-01-31 CN disclosed
WO-2022078407-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 WO disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR KCNH2 1462/4885PYGL 819/4885PDE2A 84/4885
US-12552791-B2 Heterocyclic GLP-1 agonists GLP1R, NPY1R, NPY2R KCNH2 466/4885PYGL 1289/4885PDE2A 856/4885
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR KCNH2 1462/4885PYGL 819/4885PDE2A 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.